Flash FinanceUS
Pre-market S&P 5007,549.94+2.35% Nasdaq25,253.14+2.74% Dow 3052,389.75+2.15% Russell 20002,840.81+3.15% Nasdaq-10027,907.62+3.40% MidCap 4003,715.23+3.13% SmallCap 6001,722.37+2.89% VIX19.92-22.31% 10Y Yield4.86+0.10% Close of Nov 09, 2026
AI brief of an SEC Form 8-K · Quoin Pharmaceuticals Ltd. (QNRX)

Quoin Publishes Peer-Reviewed Paper on QRX003 for Netherton Syndrome

Neutral Impact 2 of 5 product/contract Written later

Quoin Pharmaceuticals announced the online publication of a peer-reviewed paper introducing its investigational lotion QRX003 and a single pediatric compassionate-use case report. The filing presents single-patient observations only and does not report new trial results, revenue, or financial measures, so the announcement is clinical-awareness news rather than a financial result.

Key points

  • Paper published online October 13, 2026 in Dermatology and Therapy and announced October 20, 2026
  • Single pediatric patient's IGA score improved from 4 (severe) to 1 (almost clear) after six weeks and reached 0 by eight months
  • Company expects to complete recruitment of 20 participants in Phase 2/3 study CL-QRX003-004 by end of 2026 and report topline data in Q2 2027

The filing

CompanyQuoin Pharmaceuticals Ltd. (QNRX)
Form8-K, current report
Filed with the SECOct 20, 2026, 6:35 AM ET
Accession number0001104659-26-117080

Items reported: 7.01 Regulation FD Disclosure8.01 Other Events

Read the filing on SEC.gov ↗

Written by AI on Nov 9, 2026, 8:53 AM ET, from this filing only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on October 20, 2026.

Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.